ISRCTN92624244 https://doi.org/10.1186/ISRCTN92624244

The efficacy and safety of strontium ranelate versus placebo in the treatment of knee osteoarthritis

Submission date	Recruitment status	[ ] Prospectively registered
11/03/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
14/04/2010	Completed	[X] Results
Last Edited	**Condition category**	[ ] Individual participant data
28/03/2018	Musculoskeletal Diseases	

Plain English summary of protocol
Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)
Scientific

Contact name
Prof Feng Chun Zhang

Contact details
Rheumatology and Clinical Immunology Division
Department of Medicine
Peking Union Medical College Hospital
Chinese Academy of Medical Science
No.1 Shuaifuyuan, Wangfujing
Beijing
China
100730

Additional identifiers

Protocol serial number
CL3-12911-022

Study information

Scientific Title

The efficacy and safety of two doses of strontium ranelate versus placebo administered orally for 3 years in the treatment of knee osteoarthritis: a prospective multicentre, international, double-blind, placebo-controlled study

Study objectives
To demonstrate the superiority of strontium ranelate versus placebo against articular cartilage damage progression over three years in men and women with knee osteoarthritis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval was obtained before recruitment of the first participants

Primary study design
Interventional

Study design
Randomised double-blind parallel-group placebo-controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Osteoarthritis

Interventions
The treatment is composed of two doses of strontium ranelate (1 g and 2 g per day) administered orally for 3 years.

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Strontium ranelate

Primary outcome(s)
Radiographic assessment of knee osteoarthritis measured up to 36 months

Key secondary outcome(s)
Measured up to 36 months:
1. Algofunctional assessment
2. Physical examination
3. Safety

Completion date
30/04/2013

Eligibility

Key inclusion criteria
1. Asia men and women of at least 50 years of age
2. Primary knee osteoarthritis

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. Knee prosthesis already implanted or foreseen within the next year
2. Hip prosthesis recently implanted (less than 1 year) or not well-tolerated, or foreseen within the next year

Date of first enrolment
30/06/2008

Date of final enrolment
30/04/2013

Locations

Countries of recruitment
China

Korea, South

Taiwan

Study participating centre
Rheumatology and Clinical Immunology Division
Beijing
China
100730

Sponsor information

Organisation
Institut de Recherches Internationales Servier (France)

ROR
https://ror.org/034e7c066

Funder(s)

Funder type
Industry

Funder Name
Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No